Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2013 | 04:37pm CEST

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORP
03/24 EDWARDS LIFESCIENCES : Medical Appliances Stocks Under Scanner -- Neovasc, Holog..
03/23 EDWARDS LIFESCIENCES : Patent Issued for Knotless Suture Fastener Installation S..
03/23 EDWARDS LIFESCIENCES : An Application for the Trademark "THV" Has Been Filed by ..
03/23 EDWARDS LIFESCIENCES' : Trademark Application for "CONNECTED INSIGHTS" Filed
03/22 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Ma..
03/16 EDWARDS LIFESCIENCES : An Application for the Trademark "PEDIASAT" Has Been File..
03/16 BOSTON SCIENTIFIC : Receives Favorable Rulings In Edwards Lifesciences Litigatio..
03/16 EDWARDS LIFESCIENCES : Patent Issued for Holder and Deployment System for Surgic..
03/15 Global Medical Pressure Sensors Market-Edwards Lifesciences, First Sensor AG,..
03/10 GERMAN COURT RULES IN FAVOR OF BOSTO : BSX) In Patent Case Against Edwards Lifes..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
07:42aDJPHILIPS : to Buy Australian pharmacy Sleep Services Firm
02/09 Infineon, Cree warn U.S. might block Wolfspeed deal
02/02 EU probes online sales in electronics, video games, hotels
01/31DJTHERMO FISHER SCIENTIFIC : Earnings, Sales Rise
01/31DJDANAHER : Revenue, Profit Rise
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
03/27 Premarket analyst action - healthcare
03/20 LivaNova Is A Very Attractive Investment With An Asymmetric Risk/Reward
03/09 Boston Scientific wins heart valve patent suit in Germany against Edwards
03/07 Repatha's Next Challenge Is Expectations
03/03 Edwards Lifesciences gets split decision in UK heart valve patent fight with ..
Advertisement
Financials ($)
Sales 2017 3 266 M
EBIT 2017 975 M
Net income 2017 736 M
Finance 2017 749 M
Yield 2017 -
P/E ratio 2017 28,43
P/E ratio 2018 25,05
EV / Sales 2017 6,01x
EV / Sales 2018 5,41x
Capitalization 20 372 M
More Financials
Chart EDWARDS LIFESCIENCES CORP
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Full-screen chart
Technical analysis trends EDWARDS LIFESCIEN...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 116 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John T. Cardis Independent Director
William J. Link Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES C..2.32%20 372
THERMO FISHER SCIENTIF..9.56%60 351
DANAHER CORPORATION10.53%59 650
BOSTON SCIENTIFIC CORP..13.64%33 515
PHILIPS1.43%29 708
INTUITIVE SURGICAL, IN..21.00%28 180
More Results